Earlier this month, Anthropic executives confirmed that the company has developed a biology wet-lab in the Bay Area to leverage its cutting edge AI models and agents to delve into deeper science problems and run physical experiments. Dario Amodei, the founder and leader of the company, has voiced his commitment to science numerous times in the past, including when he once exclaimed that he believed AI could likely find a cure to most diseases within the next 5-10 years. The goal with this wet lab will be to primarily start moving experiments beyond models and into the physical layer. As the company’s head of life sciences Eric Kauderer-Abrams confirmed , “We believe that to do biology, the final test is still and will be for a while in real lab work…We absolutely are doing that today, and I would describe our approach as being typical of what you would see in most biotech companies, where there’s some amount of that that we’re doing in our own facilities and some amount of that that we’re working with external partners on.” Although there are no specific commercial aspects yet confirmed by the company, it is clear that it wants to move life-sciences experiments beyond purely being “in-silico” and into tangible testing. With a wet lab, Anthropic now has a place to run physical experimentation. With Claude’s ability to posit millions of potential hypotheses, the opportunities are endless.

In fact, just this week, the company confirmed that the lab has made a huge discovery, entailing the finding of a novel enzyme associated with an array of DNA repeats, similar to the famous CRISPR system. The scientists explained that “after further analysis and testing in our lab, we recognized that this pattern marked a previously uncharacterized enzyme system found in bacteriophages (the viruses that infect bacteria) that we call array-associated reverse transcriptases (ART). Our work to understand the primary function of ARTs is ongoing. However, we think it is important to share such findings early, both to demonstrate Claude’s capabilities and to give the broader community insight into what we’re working on.” While significant work remains to address the practical applications and technicalities of the discovery, experts are exclaiming that this is a huge leap forward for AI enabled scientific discovery.

Undoubtedly, Anthropic is certainly not the only company that has thrown itself deeply into the world of science with AI. One legacy player that has been doing work in this arena for years is Alphabet, especially with its majority-backed Isomorphic Labs, which spun out of DeepMind in 2021. In partnership, both companies launched AlphaFold3 in 2024, which uses AI to predict the structures of proteins, DNA and RNA to advance the world of drug discovery. The models have made significant progress since then.

In a similar fashion, OpenAI has increasingly published literature around its work in life-sciences. In fact, earlier this month, the company announced the wider availability of GPT-Rosalind , its specialized model for life-sciences research. Although the company has not yet publicly announced a wet-lab dedicated to life-sciences research, needless to say that it may soon follow-suit to remain a viable contender in this arena.

Despite the cost of these initiatives, the broader scientific community seems to be largely supportive, given that AI enabled research can likely act as a significant accelerant for research breakthroughs. Time will tell to what degree these initiatives will lead to tangible, life-improving products.